#None #Dublin #XIAFLEX #Acthar Gel #Keenova

Keenova Therapeutics Reports Third Quarter 2026 Financial Results

Keenova Therapeutics plc has recently unveiled its financial performance for the third quarter of 2026, reflecting continued strong growth in its key products, Acthar Gel and XIAFLEX. These results underscore the company’s commitment to expanding its impact within the therapeutic landscape.

Key Highlights

In the third quarter of 2026, Keenova reported net sales from continuing operations totaling $550 million, marking a significant $133 million increase compared to the same period last year, attributed to robust sales in Acthar Gel and XIAFLEX. Acthar Gel alone generated $227 million in net sales, a notable 25% uplift from the previous year driven by increased patient demand. Meanwhile, XIAFLEX saw net sales of $164 million, bolstered by growing demand for treatments such as Peyronie’s disease.

Despite the increase in sales, Keenova reported a loss of $96 million from continuing operations for the quarter. However, this marked an improvement from $242 million reported in the same period last year. The enhanced financial performance was influenced by the realization of merger synergies from the company's prior merger with Endo LP and a reduction in transaction-related compensation expenses.

Strategic Developments

The CEO of Keenova, Siggi Olafsson, expressed optimism about the company's trajectory, stating, “Since our rebranding last year, we have made substantial progress toward becoming a prominent player in the branded therapeutics market.” The management reiterated its growth projections for 2026, with expectations that Acthar Gel will continue to see a growth rate between 20% to 22%, while XIAFLEX is projected to grow by 10% to 11%.

Keenova's pipeline is also progressing, with plans to submit a supplemental Biologics License Application (sBLA) for XIAFLEX aimed at treating plantar fibromatosis expected in the first quarter of 2027. In addition, the company has initiated enrollment for a Phase 3 study regarding the Hammer Toe indication, demonstrating a significant commitment to expanding their therapeutic offerings.

Financial Guidance and Future Outlook

Keenova has raised its full-year guidance for 2026, anticipating pro forma net sales to range between $2.00 billion and $2.025 billion, along with an adjusted EBITDA projected at $750 million to $770 million. This revised outlook reflects heightened forecasted growth for both Acthar Gel and XIAFLEX.

Concluding the conference call held on November 10, 2026, Keenova's leadership detailed their expectations regarding growth strategies, market positioning, and upcoming product developments that are expected to advance in the more extensive landscape of rare disease therapeutics.

With a solid financial footing and a well-laid pipeline for product expansion, Keenova Therapeutics emphasizes its commitment to improving patient outcomes while delivering sustainable value to shareholders in the years to come. This focus reflects not only a dedication to healthcare innovation but also the vast potential within the pharmaceutical market.

Keenova continues to build on its strategic initiatives aimed at fostering a stronger portfolio of branded therapeutics, ready to address the pressing medical needs across various categories including rheumatology and pulmonary care.

As Keenova moves forward, stakeholders should remain attentive to developments surrounding their growing product lines and ongoing clinical studies that promise to reshape patient treatment paradigms.